Contact

Email

jamespatrick.buteau@unimelb.edu.au

Credentials

Position
Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology

Dr James Patrick Buteau

Honorary Conjoint Fellow
The Sir Peter MacCallum Department of Oncology
76 Scholarly works
0 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
    DOI: 10.1016/j.eururo.2025.08.015
  • 2026

    Journal article

    Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial
    DOI: 10.1016/S1470-2045(26)00120-8
  • 2026

    Journal article

    Clonal Hematopoiesis after177 Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
    DOI: 10.1158/1078-0432.CCR-25-4001
  • 2026

    Journal article

    [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
    DOI: 10.1016/S1470-2045(26)00017-3
  • 2026

    Journal article

    Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial
    DOI: 10.1016/j.euo.2024.11.006
  • 2026

    Journal article

    From salvage to spotlight: how 2025 transformed PSMA radioligand therapy
    DOI: 10.1111/bju.70282
  • 2026

    Journal article

    Avoiding Prostate Biopsy in Early Prostate Cancer Detection: From Liquid Biopsy to PSMA-PET
    DOI: 10.1016/j.euf.2026.05.019
James Patrick Buteau

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Radioligand Therapy for Prostate Cancer – A Clinical Consultation Guide
    DOI: 10.1016/j.euf.2026.06.014
  • 2026

    Journal article

    Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial
    DOI: 10.1016/j.euf.2026.05.017
  • 2025

    Journal article

    Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
    DOI: 10.2967/jnumed.125.270804